Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short chemo-radioimmunotherapy with rituximab-based chemotherapy followed by Zevalin for relapsed follicular lymphoma
2007-000222-51Phase 2Terminated
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan and rituximab in follicular lymphoma (FL), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Overall response rate, Complete response and 1 more. Started Jun 2007; status: terminated.
02
Drugs
ibritumomab tiuxetanrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2007-000222-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000222-51.